Compare FDMT & AWF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDMT | AWF |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.3M | 819.2M |
| IPO Year | 2019 | N/A |
| Metric | FDMT | AWF |
|---|---|---|
| Price | $10.21 | $9.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $28.09 | N/A |
| AVG Volume (30 Days) | ★ 855.5K | 435.6K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.57% |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $6.96 | $9.40 |
| 52 Week High | $16.93 | $10.87 |
| Indicator | FDMT | AWF |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 41.00 |
| Support Level | $8.43 | $9.42 |
| Resistance Level | $10.61 | $10.24 |
| Average True Range (ATR) | 0.85 | 0.08 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 1.07 | 17.11 |
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.